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Abstract
Background: Currently, the implementation of dosimetry in molecular radiotherapy
(MRT) is not well investigated, and in view of the Council Directive (2013/59/Euratom),
there is a need to understand the current availability of dosimetry-based MRT in clinical
practice and research studies. The aim of this study was to assess the current practice
of MRT and dosimetry across European countries.
Methods: An electronic questionnaire was distributed to European countries. This
addressed 18 explicitly considered therapies, and for each therapy, a similar set of
questions were included. Questions covered the number of patients and treatments
during 2015, involvement of medical specialties and medical physicists, implementation
of absorbed dose planning, post-therapy imaging and dosimetry, and the basis of
therapy prescription.
Results: Responses were obtained from 26 countries and 208 hospitals, administering
in total 42,853 treatments. The most common therapies were 131I-NaI for benign thyroid
diseases and thyroid ablation of adults. The involvement of a medical physicist (mean
over all 18 therapies) was reported to be either minority or never by 32% of the responders.
The percentage of responders that reported that dosimetry was included on an always/
majority basis differed between the therapies and showed a median value of 36%. The
highest percentages were obtained for 177Lu-PSMA therapy (100%), 90Y microspheres of glass
(84%) and resin (82%), 131I-mIBG for neuroblastoma (59%), and 131I-NaI for benign thyroid
diseases (54%). The majority of therapies were prescribed based on fixed-activity protocols.
The highest number of absorbed-dose based prescriptions were reported for 90Y
microsphere treatments in the liver (64% and 96% of responses for resin and
glass, respectively), 131I-NaI treatment of benign thyroid diseases (38% of responses),
and for 131I-mIBG treatment of neuroblastoma (18% of responses).
Conclusions: There is a wide variation in MRT practice across Europe and for different
therapies, including the extent of medical-physicist involvement and the implementation
of dosimetry-guided treatments.
Keywords: Molecular radiotherapy, Radionuclide therapy, Radiopharmaceutical therapy,
European survey, Dosimetry
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Background
Molecular radiotherapy (MRT) refers to the use of internally distributed, un-
sealed radioactive substances for the treatment of benign and malignant dis-
eases. These radioactive substances, namely radiopharmaceuticals, represent the
combination of an unstable radionuclide with an active or pharmacologically
inert molecule. The energy released by the radionuclide at decay determines or
boosts the therapeutic effect of the vector molecule. Initial reports of MRT in
humans date back to the period between 1938 and 1939, when several patients
suffering from chronic myeloid and lymphoid leukemia were treated with re-
peated oral administrations of 32P sodium phosphate, which accumulates in
blood cells [1].
Therapeutic radiopharmaceuticals are often administered intravenously, although
oral, intra-cavity, and intra-arterial administrations are also employed. They are
designed to accumulate in a target tissue and, if administered systemically, are able
to simultaneously treat disseminated disease which represents a clear advantage
over other more localized radiotherapy modalities. Suitable radionuclides for ther-
apy emit particle radiation, such as electrons from β−-decay or alpha particles, and
have a longer physical half-life compared to radionuclides used for diagnostic pur-
poses. In addition, most therapeutic radionuclides have associated nuclear emis-
sions (positrons or gamma rays) or yield bremsstrahlung during the slowing-down
of electrons. The resulting photon radiation can be detected by external probes or
imaged by scintillation cameras, either in planar mode or employing single-photon
(SPECT) or positron emission (PET) tomography, offering the unique possibility of
live imaging and measurement of the distribution of the therapeutic agent in vivo.
Based on the results of such measurements, the distribution of activity and
absorbed dose can be individually determined for the relevant organs and target
tissues.
For radiotherapy modalities such as external beam radiotherapy or brachyther-
apy, it would not be acceptable to treat patients without an accurate therapy
planning, including determination of the absorbed doses delivered to target tis-
sues and to organs at risk. For MRT, however, personalized dosimetry-based
treatments have been the slowest to develop among the existing radiotherapy mo-
dalities. A forthcoming Council Directive (2013/59/Euratom) [2] mandates the
use of dosimetry-based treatment planning and verification of the absorbed doses
delivered. In Chapter VII, Medical Exposures, Article 56, Optimisation, it is
stated that:
For all medical exposure of patients for radiotherapeutic purposes, exposures of target
volumes shall be individually planned and their delivery appropriately verified taking
into account that doses to non-target volumes and tissues shall be as low as reasonably
achievable and consistent with the intended radiotherapeutic purpose of the exposure.
According to the same Directive (Chapter II, Definitions, Article 4, Definitions):
“radiotherapeutic” means pertaining to radiotherapy, including nuclear medicine for
therapeutic purposes.
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This directive is to be implemented in national legislations by 6 February 2018.
The EANM Internal Dosimetry Task Force (IDTF) was formed to address aspects of
the 2013/59/ Euratom Directive specifically concerned with dosimetry for MRT. This
task force has representation from Belgium, Czech Republic, Germany, Greece, Italy,
The Netherlands, Norway, Spain, Sweden, Switzerland, Turkey, and the UK. To the
best of the knowledge of this group, the current practice of MRT and implementation
of dosimetry in clinical routine and research is poorly investigated. In 1999, results
from a questionnaire distributed among EANM representatives were reported [3],
which mainly addressed the practice of MRT from a clinical and medical point of view.
A wide variation in therapy practice across European centers was revealed, and the
authors concluded that there was a need of more uniform guidelines and legislations.
Since then, the role of MRT has expanded, as more radiopharmaceuticals and treat-
ments have been introduced. Hence, the motivation has grown to undertake a survey
with the aim of defining a clear picture of the practice and variation in MRT across
Europe and the current readiness of compliance with the 2013/59/Euratom Directive.
Methods
The survey was developed by the IDTF and focused on treatments given during the
year 2015. It was written in English and implemented in a web-based questionnaire.
The survey was structured so that it could be completed from start to end or by navi-
gating to particular therapies by choice. It could also be saved and continued at a later
time. An introductory page explained the survey aim, gave an overview of the included
therapies, and contained an option to accept or decline that results, if anonymized but
traceable to the country, would be made public.
Survey on therapies
The electronic questionnaire was constructed as one page per therapy. There were 18
explicitly considered therapies, as listed in Table 1. In addition to these, there were
three pages for “Therapy using alpha emitting radionuclides other than 223Ra” and
three pages for “Therapy using other radiopharmaceutical.”
Each therapy page consisted of three sections. The first section was common for all therap-
ies and addressed (a) the number of patients and treatments performed in 2015, (b) the med-
ical specialty owning the license to administer treatment, (c) whether a medical physicist was
involved in each treatment, (d) if the absorbed dose was individually planned, (e) whether
post-therapy imaging was conducted, and (f) if post-therapy dosimetry was performed.
The second section concerned the basis of prescription for the particular therapy
with 12 possible options (Table 2). The typical options included were 1–6 and 12, and
multiple replies could be given. Alternative 7 was included for treatments using 32P
sodium-phosphate or 90Y-ibritumomab-tiuxetan, whereas alternatives 8–11 were
included for 90Y microsphere therapies. The subsequent questions specified the rele-
vant responses, asking for the amount and unit of the prescription.
The third section concerned other therapy-specific questions. These included (a) whether
or not the therapy is generally repeated, (b) the typical repetition frequency, and (c) for which
reason a planned sequence of therapies would be discontinued. The response types in this
section were given as drop-down lists, multiple choice questions, or free-text comments.
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The final page concerned more general questions, on (a) the satisfaction of the current
implementation of patient-specific dosimetry in the center, (b) which factors limit its im-
plementation, and (c) whether any research was conducted. The time required for
responding was largely determined by the number of therapies that a particular center
was providing and whether data on patient statistics over 2015 had been compiled prior
to responding. The survey was launched June 6, 2016, by the EANM Office and via the of-
ficial route by the EANM National delegates in 40 different countries.1 In July 2016, kind
reminders were sent to the delegates and the survey was also distributed via other chan-
nels such as national networks, societies of medical physicists and nuclear medicine prac-
titioners, as well as personal contacts. The survey was closed on September 16, 2016.
Data analysis
All entries in the web-database were exported to a file and curated manually. This
process included merging records and removing duplicate entries and inconsistent data.
The spreadsheet was then imported, processed, and analyzed in the Interactive Data
Language (IDL, Harris Geospatial Solutions, Broomfield, CO).
Results
The total number of responders was 208, geographically distributed over 26 countries
in Europe, as shown in Fig. 1.
Table 1 Therapy types included in the survey, each on a separate page. Therapies A–R were
explicitly asked for, while S–U and V–X were included as complement
Annotation Therapy type
A 131I-NaI for benign thyroid diseases
B 131I-NaI for thyroid remnant ablation of adults
C 131I-NaI for thyroid remnant ablation of children and young adults
D 131I-NaI for thyroid cancer therapy for adults
E 131I-NaI for thyroid cancer therapy for children and young adults
F 131I-mIBG for neuroblastoma
G 131I-mIBG for adult neuroendocrine tumors
H 177Lu-somatostatin analogues for neuroendocrine tumors
I 90Y-somatostatin analogues for neuroendocrine tumors
J 177Lu-PSMA therapy of castration resistant prostate cancer
K 90Y resin microspheres (SIR-Spheres®) for intra-arterial treatments in the liver
L 90Y glass microspheres (TheraSphere®) for intra-arterial treatments in the liver
M Radiation synovectomy using 90Y-, 186Re-, or 169Er-colloids
N 153Sm-EDTMP (Quadramet®) for bone metastases
O 89SrCl2 (Metastron®) for bone metastases
P 223RaCl2 (Xofigo®) for bone metastases
Q 32P sodium-phosphate (Na3
32PO4) for myeloproliferative disease
R 90Y-ibritumomab-tiuxetan (Zevalin®) for B-cell lymphoma
S–U Therapy using alpha emitting radionuclides other than 223Ra
V–X Therapy using other radiopharmaceutical
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Number of patients and number of treatments
Table 3 shows the number of treatments per center in different countries, as well as
the total number of treatments. In total, 34,838 patients were reported to be treated in
the 208 centers, and as some therapies were administered multiple times, the total
number of treatments was slightly higher, and was 42,853. Table 3 also lists the
Table 2 Reply alternatives for the question “What basis of prescription do you typically use?”
Therapy types are denoted A–R, as listed in Table 1. Alternatives denoted “All” implies that all
therapies (A–R) included this option
No. Included in
questions
Prescription basis
1 All Fixed activity
2 All Fixed activity adjusted based on diagnosis, stage, or other clinical factors
3 A–J, M–R Fixed activity calculated per body surface area or patient weight
4 A–J, N–R Individually calculated activity to give a prescribed absorbed dose to whole body
5 A–J, N–R Individually calculated activity to give a prescribed absorbed dose to organ at risk
6 A–J, M–R Individually calculated activity to give a prescribed absorbed dose to target tissue
7 Q, R Stepwise escalation of activity based on patient response
8 K, L Body-Surface-Area (BSA) method with reductions
9 K, L Individually calculated activity based on prescribed absorbed dose to the target
volume (lobe or segment) to be treated
10 K, L Individually calculated activity based on 99mTc MAA SPECT to give a prescribed
absorbed dose to non-tumoral liver tissue
11 K, L Individually calculated activity based on 99mTc MAA SPECT to give a prescribed
absorbed dose to tumor
12 All Other prescription
Fig. 1 Number of responding centers in different European countries. No responses were received from
countries without numbers
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percentage of treatments that represented the different procedures. Therapies involving
131I-NaI (A-E) represented 71% of the total number of treatments given and 84% of the
patients treated in total (data not shown). Of the total number of treatments, 11% were
delivered using 177Lu/90Y-somatostatin analogues (peptide-receptor radionuclide ther-
apy, PRRT) (H–I) or 177Lu-PSMA (J), 10% using 223RaCl2 (P), 3.7% with
90Y micro-
spheres (K, L) and 2.2% with radiation synovectomy (M). As seen in Table 3, the
therapies in most wide-spread use were those involving 131I-NaI, in particular for treat-
ment of benign thyroid diseases and thyroid ablation of adults. Certain therapies such
as 177Lu-PSMA (J), 90Y PRRT (I), 32P sodium-phosphate (Q), and 90Y-ibritumomab-
tiuxetan (R) were administered only in a few countries.
License to administer treatment
For the question “Which medical specialty owns the license to administer treatment?”, sev-
eral, non-exclusive replies could be chosen among the alternatives Nuclear Medicine, Med-
ical Oncology, Radiation Oncology, Endocrinology, Interventional Radiology, or Other.
Results showed a pronounced weighting towards Nuclear Medicine, for which the average
frequency for all treatments was 83%. The average frequencies for the other alternatives
were for Medical Oncology (8.5%), Radiation Oncology (6.0%), Endocrinology (1.2%), and
Interventional Radiology (1.0%). No center replied Other. The replies were similar for most
treatments, exceptions being 90Y microspheres for which Interventional Radiology was
higher at 12% and 6% for resin and glass, respectively, and 32P sodium-phosphate where the
respective frequencies were for Nuclear Medicine (59%), Medical Oncology (22%), and Ra-
diation Oncology (19%). Seventeen countries responded 100% Nuclear Medicine, while the
percentage of Nuclear Medicine for the remaining countries were Belgium (96%), Bulgaria
(42%), Denmark (92%), Ireland (58%), Italy (94%), Norway (84%), Sweden (30%), Turkey
(14%), and UK (37%), as calculated over all therapies.
Imaging, dosimetry, and involvement of medical physicist
For these set of questions, one exclusive reply consisting of Always, Majority, Minority, or
Never could be given. The numbers were expressed as frequencies for each therapy, cal-
culated as the number of times a particular response was given divided by the total num-
ber of responses for that therapy. Analysis was also made by combining the data into two
categories, namely Always/Majority versus Minority/Never, by counting the centers that
gave one of the two replies and dividing by the total number of responses for that therapy.
Figure 2a shows the responses on the question “Is a medical physicist involved in
each treatment?”. The mean frequencies for all treatments together were for Always
(63.9%), Majority (3.7%), Minority (9.7%), and Never (22.7%). When combining the data
in two categories, the frequencies were thus 67.6% and 32.4%, for Always/Majority and
Minority/Never, respectively. The median of the Always/Majority frequencies was 66%
(min 45%, max 88%). The Always/Majority frequency was 50% or higher for all therap-
ies except radiation synovectomy (45%) and 90Y-ibritumomab-tiuxetan (48%). Treat-
ments for which the Always/Majority frequency was higher than 75% were 177Lu-
PSMA (88%), 90Y PRRT (83%), 32P sodium-phosphate (83%), 131I-mIBG for neuroblast-
oma (82%), 177Lu PRRT (79%), 131I-mIBG for adult neuroendocrine tumors (77%), and
90Y microspheres of resin (84%) and glass (78%). The highest frequencies were notably
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obtained for therapies with a limited geographical spread (177Lu-PSMA: 2 countries;
90Y PPRT: 6 countries; and 32P sodium-phosphate: 4 countries).
Figure 2b shows the responses to the question “Is the absorbed dose individually
planned for each patient?”. The mean frequencies for all treatments together were for
Always (33.1%), Majority (3.5%), Minority (8.4%), and Never (55.1%). For the two
categories Always/Majority and Minority/Never, the frequencies were thus 36.5% versus
63.5%. The median of the Always/Majority frequencies was 33% (min 11%, max 84%).
a b
c d
Fig. 2 Replies for the questions a “Is a medical physicist involved in each treatment?”, b “Is the absorbed
dose individually planned for each patient?”, c “Is post-therapy imaging performed?”, and d “Is post-therapy
dosimetry performed?”. Numbers on the horizontal axis represent the percentage of the total number of
responses for a particular therapy that gave the indicated reply
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The highest frequencies were obtained for 90Y microspheres, for which 82% (resin) and
84% (glass) of the centers responded Always/Majority, and 131I-NaI for benign thyroid
diseases, where this frequency was 54%.
Figure 2c shows the response frequencies to the question “Is post-therapy imaging per-
formed?”. The mean frequencies for all treatments together were for Always (67.7%), Ma-
jority (1.6%), Minority (3.7%), and Never (27.0%). For the two categories Always/Majority
and Minority/Never, the respective frequencies were thus 69.3% and 30.7%. The median
of the Always/Majority frequencies was 94% (min 0%, max 100%). A group of therapies
had more than 50% of the centers respond Minority/Never (131I-NaI for benign thyroid
diseases, radiation synovectomy, 89SrCl2,
223RaCl2,
32P sodium-phosphate, and 90Y-ibritu-
momab-tiuxetan). 153Sm-EDTMP for bone metastases was close to 50%, whereas for the
other therapies post-therapy imaging was being conducted on an Always/Majority basis.
Figure 2d shows the response frequencies to the question “Is post-therapy dosimetry per-
formed?” The mean frequencies for all treatments together were for Always (22.0%), Major-
ity (4.4%), Minority (12.0%), and Never (61.6%). For the two categories Always/Majority and
Minority/Never, the respective frequencies were thus 26.4% and 73.6%. The median of the
Always/Majority frequencies was 23% (min 0%, max 100%). For two therapies more than
50% of the centers responded Always/Majority, 177Lu-PSMA (100%) and 131I-mIBG for
neuroblastoma (59%). For PRRT using 90Y or 177Lu, as well as 131I-mIBG for adult neuroen-
docrine tumors, approximately 40% of the centers responded Always/Majority. For the
other therapies, the responses on post-therapy dosimetry were mainly Minority/Never.
To summarize, the highest frequencies of any dosimetry, i.e., either as part of treat-
ment planning or post-therapy and on an Always/Majority basis (Fig. 2b, d), were for
177Lu-PSMA therapy (100%), 90Y microspheres of glass (84%) and resin (82%), 131I-
mIBG for neuroblastoma (59%), and 131I-NaI for benign thyroid diseases (54%). When
calculated over all therapies, the percentage of responders that reported that dosimetry
was included on an Always/Majority basis was obtained to a median of 36%.
Activity prescription
For this set of questions, several, non-exclusive replies could be given, where the alter-
natives for the different therapies are listed in Table 2. The frequencies were calculated
as the occurrence of a particular reply in relation to the total number of replies. Table 4
summarizes the most typically stated prescribed amounts, where for many therapies, a
high diversity was obtained among the different prescription alternatives. Occasional
outliers, likely caused by typographic errors, were disregarded for this summary.
For therapies involving 131I-NaI (Fig. 3a, A–E in Table 4), the majority of the
responders stated that they use different kinds of fixed-activity schemas, mainly ad-
justed based on the diagnosis, stage, or other clinical factors. For treatments (B–E), re-
sponses 1–3 were given on average for 84% of the replies, while for 131I-NaI for benign
thyroid diseases (A) these responses were given in 54% of the replies, and 71 out of the
188 different responses (38%) stated that the activity was individually calculated to give
a prescribed absorbed dose to target tissue.
Likewise, for therapies shown in Fig. 3b (F–J in Table 4) responses 1–3 were most
frequent, thus stating that fixed activities were being used, possibly adjusted based on
the diagnosis, stage or other clinical factors, or patient weight. For 131I-mIBG treatment
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of neuroblastoma (F), 8 out of 44 responses (18%) stated prescriptions based on the
whole-body absorbed dose, with a limit of either 2 or 4 Gy for two subsequent adminis-
trations. Prescriptions based on the absorbed dose to organ at risk were reported for
131I-mIBG treatment of adult neuroendocrine tumors in 5/39 of responses (13%), for
177Lu PRRT in 3/38 (8%), and for 90Y PRRT in 2/22 (9%).
For therapies shown in Fig. 3c, including radiation synovectomy, the bone seekers
153Sm-EDTMP, 89SrCl2, and
223RaCl2,
32P sodium-phosphate, and 90Y-ibritumomab-
tiuxetan, prescriptions listed as alternatives responses 1, 2, 3, 7 in Table 2, represented
96% of the replies, calculated as an average of the therapies. Prescriptions for these
therapies were thus approximately only based on fixed-activity schemas, with adjust-
ments made.
Table 4 The most commonly stated prescribed amounts for the different therapies. Therapy
notations follow Table 1, whereas prescription alternatives 1–6 refer to Table 2. The prescribed
amounts are given either as median, 10th and 90th percentiles, or as median, minimum, and
maximum, depending on the replies obtained. The percentiles are used to better accommodate
some occasional outlier values
Therapy Specification Prescription alternative according to Table 2
Alt. 1 or 2 (unit MBq) Alt.3, 4, 5, or 6 (unit as given)
Median 10th 90th Median 10th 90th
A Toxic or nontoxic multinodular goiter 550 370 740 150 120 300 Gy to target
Autonomous nodules 500 370 770 300 200 400 Gy to target
Graves’ disease 400 222 600 200 100 300 Gy to target
B Lowest prescribed amount 1110 1100 3490
Highest prescribed amount 4440 3540 7400
C Lowest prescribed amount 1110 1000 3700
Highest prescribed amount 3700 1554 6290
D Lowest prescribed amount 4000 1111 6920
Highest prescribed amount 7400 5500 10,000
E Lowest prescribed amount 3700 1100 5500
Highest prescribed amount 5525 3700 7360
M 90-Y 185 185 220
169-Er 37 17 39
186-Re 77 73 161
N 2545 – – 37 MBq/kg
O 150 148 185
P – – – 0.05–0.055 MBq/kg
Q 185 – – 3.7–3.9 MBq/kg or 74–111 MBq/m2
R – – – 11–15 MBq/kg (median 14.8 MBq/kg)
Median Min Max
F 7400 2700 9250 444 MBq/kg, or 2 or 4 Gy to whole
body
G 7400 3700 14,800 444 MBq/kg, or 2 to whole body
H 7400 4000 9175 23 or 29 Gy to kidneys
I 2600 1480 5550 1850–2500 MBq/m2, or 23 Gy to
kidneys
J 6000 3500 7400 23 Gy to kidneys
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For 90Y-microsphere treatments (K, L), shown in Fig. 3d, the replies differed from above.
In this case, the most common responses were prescriptions based on the absorbed dose, ei-
ther to the target tissue (lobe or segment), or to non-tumor liver tissue or tumor based on
99mTc-MAA SPECT (Table 2, alternatives 9–11). For resin microspheres, the frequencies
were 14/85 (15%) for alternative 9 in Table 2, 21/85 (25%) for alternative 10, and 19/85
(22%) for alternative 11. For glass microspheres, the corresponding frequencies were 23/48
(48%) for alternative 9, 13/48 (27%) for alternative 10, and 10/48 (21%) for alternative 11.
Thus, absorbed-dose based prescriptions were reported in 64% and 96% of responses for
resin and glass, respectively. There was a difference between resin and glass microspheres
in that the body-surface area method was stated in 28/85 (33%) of the responses for resin,
whereas the corresponding number for glass microspheres was 2/48 (4%).
User satisfaction
For the question “Are you satisfied with the current implementation of patient-specific dos-
imetry in your centre?”, 45% of the responders answered Yes and 55% answered No. For the
question “Which factors limit the implementation of patient-specific dosimetry in your
centre?”, the reply alternatives were non-exclusive. The listed alternatives and percentage re-
sponses were “Shortage of knowledge and know-how” (12%), “Shortage of medical physi-
cists working in nuclear medicine” (20%), “Shortage of other staff” (13%), “Limited access to
scanner or other equipment needed” (17%), “Limited access to dedicated software” (16%),
“No legislative requirement to perform dosimetry” (12%), and “Other” (10%).
Fig. 3 Replies for the question “What basis of prescription do you typically use?”. a Therapies using 131I-NaI (A–E in
Table 1). b Results for 131I-mIBG, 177Lu /90Y PRRT, and 177Lu-PSMA (F–J in Table 1). c Therapies including radiation
synovectomy, 153Sm-EDTMP, 89SrCl2, and
223RaCl2,
32P sodium-phosphate, and 90Y-ibritumomab-tiuxetan (M–R in
Table 1). d 90Y microspheres of resin or glass (K and L in Table 1). Numbers on the horizontal axis represent the
percentage of the total number of responses for a particular therapy that gave the indicated reply. The vertical axis
alternatives are numbered as listed in Table 1, where explanations of the abbreviations are given. Bar colors
correspond to those in Fig. 2
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Discussion
To the best of our knowledge, this is the first extensive survey focused on the implemen-
tation of MRT and dosimetry. As for surveys in general, results can only be considered as
a sample of an underlying true population. The extent to which the results are representa-
tive of general practice is dependent on the number of responders, their geographic
spread, how well the questions were understood, and whether they could be responded to
in a reasonable amount of time. Another factor that may influence the representativeness
of our results is that the survey was answered on a voluntary basis and there is the pos-
sible risk that centers involved in dosimetry could be more likely to respond. Moreover,
the professional role of the individual responder, e.g., physician, medical physicist, or tech-
nologist, was not asked for. For this survey, 208 responses were obtained, which we con-
sider to be good. However, results from this survey should be regarded as a starting point
with results that provide a snap-shot of the current situation.
Total number of centers administering MRT in Europe
To our knowledge, there is no current record of the number of MRTs performed in
Europe. The International Atomic Energy Agency (IAEA) keeps a database on nuclear
medicine practice around the world,2 in which the total number of therapies in differ-
ent countries is included. However, this database, intended mainly for developing coun-
tries, is compiled on a voluntary basis. As a result, the data are by no means complete
and for many European countries are below the number of therapies reported in this
survey. Furthermore, information on the different kinds of MRTs is not available in the
IAEA database. In 1999, the EANM Radionuclide Therapy Task Group reported on re-
sults from two questionnaires, distributed in 1993 to national advisors or members of
the task group, with data acquired from 16 and 20 European countries [3]. The number
of centers administering MRT in different countries was reported, identifying a total of
630 centers. In addition to that survey [3], a few national surveys have been identified
[4, 5], as well as one reviewing nuclear medicine in the Middle East [6].
To address the shortage of information and put results of the current survey into per-
spective, the ITDF made an effort, after the survey was closed, to compile data of the
number of centers that administer MRT in the countries from where responses were
obtained (Table 5). The information sources identified were the EANM national dele-
gates, national authorities or societies, published national data, and in some cases, per-
sonal communication or data retrieved from [3]. For the 25 countries where data could
be obtained, a total of 925 centers were recorded. The 208 responders in the current
survey were thus estimated to represent approximately 20% of the existing centers. For
the future, a European database of centers performing MRT would need to be estab-
lished in order to achieve complete overview of the situation. Similar initiatives have
been undertaken in external beam radiotherapy as part of the ESTRO Health Econom-
ics in Radiation Oncology project [7].
Survey construction and dissemination
For this survey, there were evident challenges in reaching responders, resulting in an ir-
regular response rate between countries (Fig. 1 and Table 5). Following the initial
launch via the official route of dissemination, the response rate was rather modest, and
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we partly relied on national networks through which the survey could be forwarded.
The construction of the survey lasted almost 1 year and built upon discussions in the
ITDF, taking the different national perspectives into account, and the fact that different
radionuclide therapies have different treatment aims, procedures for administration, level
of patient hospitalization, profiles of treatment-related risks, and ease of implementation
of dosimetry. During these discussions, a number of potential problems were identified,
especially concerning the terminology that is not well established. For instance, the
modality itself runs under various names such as “nuclear medicine therapy,” “radiophar-
maceutical therapy,” and “(targeted) radionuclide therapy,” in addition to “molecular
radiotherapy,” as used herein. Another ambiguous term is the word “treatment,” which
for radionuclide therapies involving planned repeated administrations may refer to one
administration or a series of administrations. Here, terms such as “fraction” or “treatment
Table 5 Number of centers that administer molecular radiotherapy in the countries from where
responses were obtained. Numbers have been acquired from a variety of sources, as indicated, and
are valid for 2015–2016 except where explicitly stated otherwise
Country Number of
centers
Source of information
Albania No information
Austria 7 Only number of inpatient facilities, personal communication
Belgium 143 Number of licensed sites. Registry of the Belgian Federal Agency for
Nuclear Control
Bosnia and
Herzegovina
3 EANM National Delegate
Bulgaria 11 EANM National Delegate
Croatia 6 EANM National Delegate
Cyprus 5 Ministry of Health (public hospitals) and personal communication
(private hospitals)
Czech Republic 47 Institute of Health Information and Statistics of the Czech Republic
(online)
Denmark 14 EANM National Delegate
France 60 Valid 1999, reference [3]
Germany 114 Valid 2012, reference [5]
Greece 33 Greek Atomic Energy Comission
Hungary 13 EANM National Delegate
Ireland 14 EANM National Delegate
Italy 106 Valid 2006, White paper of Italian Association of Nuclear Medicine
(online)
Latvia 1 EANM National Delegate
Netherlands 66 Valid 2014, Dutch health research institute (online)
Norway 19 Norwegian Radiation Protection Authority
Portugal 32 Ministry of Health of Portugal
Serbia 7 EANM National Delegate
Slovakia 16 National Health Information Center (Slovakia)
Spain 90 National Safety Council of Spain
Sweden 24 Swedish Society of Radionuclide Therapy (online)
Switzerland 13 Only number of inpatient facilities, personal communication
Turkey 11 Valid 1999, reference [3]
United Kingdom 70 Estimated, personal communication
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cycle” have sometimes been borrowed from other treatment modalities although these
may be more or less suited within the context of particular therapies. The need to develop
standardized terminology is thus evident. For the question concerning the involvement of
a medical physicist, it was recognized that the word “involved” could be clarified further.
However, also in the Council Directive (2013/59/Euratom), the word “involved” is being
used without clarification, and seeing that one of the aims was to understand the compli-
ance to that Directive, it was decided to maintain this wording. The prescription basis was
particularly difficult to summarize in a few questions, in view of the quite different treat-
ment protocols applied in different countries and within countries. To some extent, this
can be seen as a result in its own, pointing to the diversity of treatment protocols that are
being employed for patients in Europe.
Results for treatments, the use of dosimetry, and the involvement of medical physicists
The most commonly performed therapies were clearly 131I-NaI for benign thyroid
diseases and thyroid ablation of adults (Table 3, therapies A and B). These were also the
therapies with largest geographical spread. As shown in Fig. 2, 54% of the responses stated
that absorbed-dose planning was being undertaken in treatments of benign thyroid
diseases in Always/Majority of treatments, while the same number, 54%, responded that a
medical physicist was involved (Always/Majority). For 131I-NaI thyroid ablation of adults,
23% of the responses stated that absorbed-dose planning was undertaken and 21% that
post-therapy dosimetry was performed in Always/Majority of treatments, while 55%
responded that a medical physicist was involved (Always/Majority). Overall, this suggests
that approximately 50% of the responding centers administer these treatments (A and B)
without involvement of a medical physicist and without any dosimetry.
The most concerning results are perhaps those presented in Fig. 2a, showing an aver-
age frequency of the Minority/Never responses for involvement of a medical physicist
of 32%. Without the involvement of a medical physicist, the likelihood that dosimetry
can be undertaken is probably low. This may also explain the confusion that was occa-
sionally encountered in the free-text replies, of the generic term dose (for instance in
units of MBq), versus the SI-derived quantity absorbed dose (in unit Gy). The survey
questions clearly distinguished between activity and absorbed dose and did not use the
term “dose” without specification. Thus, the possible confusion between administered
activity and absorbed dose was not likely caused by the wording of the survey ques-
tions. However, seeing that the general term “dose” is often used in nuclear medicine,
misunderstandings may still exist.
Among the therapies not involving 131I-NaI, 223RaCl2 therapies for bone metastases
accounted for 3.3% of the total patients treated (data not shown). Given that repeated
administrations are foreseen in the therapy protocol [8], this corresponded to 10% of
the total radionuclide treatments in our survey (Table 3, therapy P). Concerning the
geographical spread, 13 of the countries from which responses were obtained gave this
treatment. This is a comparably high number in view of the short history of this ther-
apy. Although imaging and dosimetry of 223RaCl2 presents several challenges [9–11],
38% of centers responded that the absorbed dose was individually planned, 17% that
post-therapy imaging was performed, and 4% that post-therapy dosimetry was per-
formed, on an Always/Majority basis. In view of the practical difficulties in performing
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absorbed-dose planning for 223RaCl2 and that 98% of responses on the activity prescrip-
tion stated different kinds of fixed-activity protocols, these figures appear unlikely and
raise the question on the understanding of the concept of individual-based absorbed-
dose determination. It is possible that responders did not distinguish between an indi-
vidually calculated absorbed dose and the absorbed-dose estimation per unit of admin-
istered activity available in the package insert.
Other comparably frequent treatments were 177Lu or 90Y PRRT (Table 3, therapies H
and I). PRRTs are given as repeated administrations, and while the percentages of the
treated patients were 3% (H) and 1% (I) (data not shown), the percentages of the given
number of treatments were 6% (H) and 5% (I). Concerning the geographical spread, 13
out of the 26 countries were administering either of these treatments. This is a rela-
tively high proportion considering that neither of these therapies is yet approved for
clinical use by the European Medicines Agency (EMA). For the responses Always/Ma-
jority (Fig. 2), 15% (H) and 33% (I) of centers responded that the absorbed dose was in-
dividually planned, 100% (H) and 89% (I) that post-therapy imaging was performed,
and 44% (H) and 39% (I) that post-therapy dosimetry was performed. These results ap-
pear somewhat more consistent than for 223RaCl2, since the practical implementation
of imaging and post-therapy dosimetry is more straightforward [12, 13], and since with-
out EMA approval, these therapies are probably to a larger extent administered as part
of clinical trials.
The most frequent application of any dosimetry, i.e., responses in the Always/Major-
ity category either as part of treatment planning or on a post-therapy basis (Fig. 2), was
reported for 177Lu-PSMA (100%), 90Y microspheres of glass (84%) and resin (82%),
131I-mIBG for neuroblastoma (59%), and 131I-NaI for benign thyroid diseases (54%).
Possible explanations for these results are that 177Lu-PSMA is yet not approved for
clinical use by the EMA and is thus being evaluated as part of clinical trials in a limited
number of centers (2 of the 26 countries). For 90Y microspheres, the risks for
radiation-induced liver disease are of clinical concern, and at the same time, patient-
specific dosimetry can be accomplished using only one patient scan [14]. Dosimetry in
131I-mIBG for neuroblastoma is particularly motivated in view of the pediatric/young
patient population. The implementation of dosimetry in 131I-NaI treatments for benign
thyroid disease is compulsory in some countries, which may explain the geographical
variability, as further highlighted in Fig. 4.
Free-text comments from the responders
The free-text fields were available on the survey for collecting additional comments
from the participants. For instance, some pointed at the lack of information on the tol-
erance levels of normal organs as an obstacle for clinical implementation of dosimetry,
while others argued that prospective, randomized trials for examining the clinical value
of dosimetry are needed before implementation. Others pointed at needs for resources
and equipment, methodological guidance, and standardization of dosimetry methods.
According to the questions on user satisfaction, 45% of the responders were satisfied
with the implementation of dosimetry in their center. Interestingly, 12% of responders
stated that a limiting factor was that there is no legislative requirement to perform
dosimetry.
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Summary
In summary, our European survey showed a wide variation in MRT and dosimetry
practices. Although MRT has a long history of being prescribed based on different
fixed-activity schemas, with successful treatment results obtained in patient groups, this
does not mean that the treatment is also optimal for an individual patient. For instance,
it has been demonstrated that, for a given administered activity, the absorbed dose to
target tissue may vary by more than two orders of magnitude for the same treatment
[15]. Correlations between estimated absorbed doses and clinical outcomes have been
reported for several types of MRTs [16–22], and some therapeutic prescriptions are
already based on dosimetry [23–28]. It is likely that additional therapeutic scenarios
would benefit from dosimetry studies. In fact, for some therapies, fixed activities might
be too conservative, and patient-based dosimetry might indicate the need for activity
escalation in order to achieve the desired dose to the target. On the other hand, in
some other cases, dosimetry studies might constrain the activity prescriptions to keep
the absorbed doses to non-target organs within safe limits or rule out patients who
would not achieve enough absorbed doses to the target, helping to balance risks and
benefits on a single patient basis. Furthermore, as pointed out already in 1992 [29],
there may be economical incentives for implementation of dosimetry. These authors re-
ported on results of dosimetry-based 131I-NaI thyroid cancer therapy for adults and
found that the savings made on a lower rate of hospitalization well balanced the extra
costs for dosimetry. Bearing in mind that we are in an era when personalized treat-
ments are the focus of many kinds of radiotherapy, as well as pharmaceutical therapies,
Fig. 4 Percentage of responses from different countries who stated Always or Majority on the question “Is
the absorbed dose individually planned for each patient?” for 131I-NaI treatment of benign thyroid diseases.
Only countries represented by 3 or more responders are included
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MRT has an extraordinary advantage in that the pharmaceutical agent and its distribu-
tion over time can be monitored and quantified.
Conclusion
There is a wide variation in MRT practice across Europe, including the extent of
medical-physicist involvement and the implementation of dosimetry-guided treatments.
In many cases, dosimetry is feasible, and several therapies exist in which dosimetry is
being performed on a fairly standardized basis in different centers and countries. How-
ever, in respect of the Council Directive (2013/59/Euratom), it appears that there is still
a general need to increase the possibilities and benefits of a higher degree of implemen-
tation of dosimetry.
Endnotes
1See http://www.eanm.org/about/organs/national-societies/ for a complete list of na-
tional societies.
2http://nucmedicine.iaea.org/
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